Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma

Expert Opinion on Therapeutic Targets

Volumn 6, Issue 1, 2002, Pages 103-113

  Graff, Jeremy R ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

AKT; Androgen dependence; Androgen independence; Cyclin D1; Forkhead transcription factors; mTOR; p27KIP1; Prostate cancer; PTEN; Translational control

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANDROGEN; ANTIANDROGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAPAMYCIN; TEMSIROLIMUS; WORTMANNIN; AKT1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; ONCOPROTEIN; PROTEIN SERINE THREONINE KINASE;

ANGIOGENESIS; APOPTOSIS; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CELL CYCLE; CELL PROLIFERATION; CLINICAL FEATURE; CLINICAL TRIAL; HUMAN; KIDNEY CARCINOMA; LUNG SMALL CELL CANCER; METASTASIS; NONHUMAN; PROSTATE ADENOCARCINOMA; PROTEIN FUNCTION; REVIEW; TREATMENT DURATION; ADENOCARCINOMA; ANIMAL; DRUG EFFECT; GENETICS; MALE; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 0036479998     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.6.1.103     Document Type: Review

References (66)

1. ZHAO XY, FELDMAN D: The role of vitamin D in prostate cancer. Steroids (2001) 66:293-300.
2. RUIJTER E, VAN DE KAA C, MILLER G, RUITER D, DEBRUYNE F, SCHALKEN J: Molecular genetics and epidemiology of prostate carcinoma. Endocr. Rev. (1999) 20(1):22-45.
3. ABATE-SHEN C, SHEN MM: Molecular genetics of prostate cancer. Gene Dev. (2000) 14:2410-2434. •• An excellent review of the molecular alterations involved in prostatic carcinogenesis and progression.
4. CHANG BL, ZHENG SL, ISAACS SD et al.: Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer. Int. J. Cancer (2001) 95(6):354-359.
5. GOODE EL, STANFORD JL, PETERS MA et al.: Clinical characteristics of prostate cancer in an analysis of linkage to four putative susceptibility loci. Clin. Cancer Res. (2001) 7(9):2739-2749.
6. ZHENG SL, XU J, ISAACS SD et al.: Evidence for a prostate cancer linkage to chromosome 20 in 159 hereditary prostate cancer families. Hum. Genet. (2001)108(5):430-435.
7. ISAACS JT: The biology of hormone refractory prostate cancer. Why does it develop? Urol. Clin. North Am. (1999) 26:263-273. •• Thorough discussion of the biology of androgen-independent prostate cancer.
8. GULLEY J, ARLEN P, DAHUT W: Treating systemic prostate cancer emerging drug targets and therapies. Emerging Ther. Targets (2000) 4(6):751-763.
9. DREICER R: The evolving role of hormone therapy in advanced prostate cancer. Cancer Diag. Manag. (2000) 67(10):720-726.
10. MELCHIOR SW, COREY E, ELLIS WJ et al.: Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. Clin. Cancer Res. (1997) 3(2):249-256.
11. BOSTWICK DG, SHAN A, QIAN J et al.: Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma. Cancer (1998) 83(9):1995-2002.
12. CRAFT N, CHHOR C, TRAN C et al.: Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen dependenr tumors through a two step process. Cancer Res. (1999) 59:5030-5036. • Study showing androgen-independent CaP cells pre-exist in early CaP.
13. AGUS DB, CORDON-CARDO C, FOX W et al.: Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J. Natl. Cancer Inst. (1999) 91(21):1869-1876. • Study detailing the alterations that characterise the emergence of the androgen-independent phenotype.
14. ISAACS JT, COFFEY DS: Adaptation vs. selection as the mechanism responsible for the relapse of prostatic cancer androgen therapy as studied in the Dunning R-2337-H adenocarcinoma. Cancer Res. (1981) 41(12):5070-5075.
15. DROBNJAK M, OSMAN I, SCHER HI, FAZZARIM, CORDON-CARDO C: Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin. Cancer Res. (2000) 6(5):1891-1895.
16. HAN EK, LIM JT, ARBER N, RUBIN MA, XING WQ, WEINSTEIN IB: Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate (1998) 35(2):95-101.
17. ITTMANN MM: Chromosome 10 alterations in prostate adenocarcinoma. Oncol. Rep. (1998) 5(6):1329-1335.
18. CAIRNS P, OKAMI K, HALACHMI N et al.: Frequent inactivation of PTEN/ MMAC1 in primary prostate cancer. Cancer Res. (1997) 57(22):4997-5000.
19. VAZQUEZ F, SELLERS WR: The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim. Biophys. Acta (2000) 1470:M21-M35. • Thorough review of PTEN function and loss, particularly in advanced CaP.
20. MCMENAMIN ME, SOUNG P, PERERA S, KAPLAN I, LODA M, SELLERS WR: Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high gleason score and advanced stage. Cancer Res. (1999) 59:4291-4296. • Key study linking PTEN loss to advanced prostate cancer.
21. PESCHE S, LATIL A, MUZEAU F et al.: PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene (1998) 16(22):2879-2883.
22. DONG JT, SIPE TW, HYYTINEN ER et al.: PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene (1998) 17:1979-1982.
23. GIRI D, ITTMANN MM: Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. Hum. Pathol. (1999) 30(4):419-424.
24. WANG SI, PARSONS R, ITTMAN MM: Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin. Cancer Res. (1998) 4(3):811-815.
25. KWABI-ADDO B, GIRI D, SCHMIDT K et al.: Haploinsufficiency of the PTEN tumor suppressor gene promotes prostate cancer progression. Proc. Natl. Acad. Sci. USA (2001) 98(20):11563-11568.
26. WHANG YE, WU X, SUZUKI H et al.: Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostare cancer through loss of expression. Proc. Natl. Acad. Sci. USA (1998) 95:5246-5250.
27. VLIETSTRA RJ, VAN ALEWIJK DC, HERMANS KG, VAN STEENBRUGGE GJ, TRAPMAN J: Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res. (1998) 58:2720-2723.
28. DI CRISTOFANO A, PESCE B, CORDON-CARDO C, PANDOLFI PP: PTEN is essential for embryonic development and tumor suppression. Nat. Genet. (1998) 19:348-355.
29. PODSYPANINA K, ELLENSON LH, NEMES A et al.: Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. USA (1999) 96:1563-1568.
30. CANTLEY LC, NEEL BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. USA (1999) 96:4240-4245. • Thorough review of the PTEN/AKT pathway.
31. LEEVERS SJ, VANHAESEBROECK B, WATERFIELD MD: Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr. Opin. Cell Biol. (1999) 11(2):219-225.
32. RAMASWAMY S, NAKAMURA N, VAZQUEZ F et al.: Regulation of the G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. USA (1999) 96:2110-2115. • Study showing that consequences of PTEN loss are largely due to AKT activation.
33. WU X, SENEGAL K, NESHAT MS, WHANG YE, SAWYERS CL: The PTEN/ MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. USA (1998) 95:15587-15591.
34. COFFER PJ, JIN J, WOODGETT JR: Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem. J. (1998) 335:1-13.
35. BALENDRAN A, CASAMAYOR A, DEAK M et al.: PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2. Curr. Biol. (1999) 9(8):393-404.
36. TOKER A, NEWTON AC: Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2site. J. Biol. Chem. (2000) 275(12):8271-8274.
37. PERSAD S, ATTWELL S, GRAY V et al.: Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J. Biol. Chem. (2001) 276(29):27462-27469.
38. 473 phosphorylation.
39. LYNCH DK, ELLIS CA, EDWARDS PA, HILES ID: Integrin-linked kinase regulates phosphorylation of serine 473 of protein kinase B by an indirect mechanism. Oncogene (1999) 18:8024-8032.
40. KENNEDY SG, KANDEL ES, CROSS TK, HAY N: Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol. Cell. Biol. (1999) 19(8):5800-5810.
41. DATTA SR, DUDEK H, TAO X et al.: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell (1997) 91(2):231-241.
42. CARDONE MH, ROY N, HENNING R et al.: Regulation of cell death protease caspase-9 by phosphorylation. Science (1998) 282:1318-1321.
43. NESTEROV A, LU X JOHNSON M, MILLER GJ, IVASHCHENKO Y, KRAFT AS: Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J. Biol. Chem. (2001) 276(14):10767-10774.
44. KANE LP, SHAPIRO VS, STOKOE D, WEISS A: Induction of NF-kappaB by the Akt/PKB kinase. Curr. Biol. (1999) 9(11)601-604.
45. MADRID LV, WANG CY, GUTTRIDGE DC, SCHOTTELIUS AJG, BALDWIN AS JR., MAYO MW: Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-κB. Mol. Cell. Biol. (2000) 20(5):1626-1638.
46. BUROW ME, WELDON CB, MELNIK LI et al.: PI-3K/AKT regulation of NF-κB signaling events in suppression of TNF-induced apoptosis. Biochem. Biophys. Res. Commun. (2000) 271:342-345.
47. BRUNET A, BONNI A, ZIGMOND MJ et al.: Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell (1999) 96(6):857-868. •• Key study linking AKT to FKHR inhibition.
48. MEDEMA RH, KOPS GJ, BOS JL, BURGERING BM: AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature (2000) 404(6779):782-787. •• Key study linking AKT activity to decreased p27KIP1 transcription.
49. BROWNAWELL AM, KOPS GJ, MACARA IG, BURGERING BM: Inhibition of nuclear import by protein kinase B (Akt) regulates the subcellular distribution and activity of the forkhead transcription factor AFX. Mol. Cell. Biol. (2001) 21(10):3534-3546.
50. NAKAMURA N, RAMASWAMY S, VAZQUEZ F, SIGNORETTI S, LODA M, SELLERS WR: Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol. Cell. Biol. (2000) 20(23):8969-8982.
51. TAKAISHI H, KONISHI H, MATSUZAKI H et al.: Regulation of nuclear translocation of forkhead transcription factor AFX by protein kinase B. Proc. Natl. Acad. Sci. USA (1999) 96(21):11836-11841.
52. BIGGS WH 3RD, MEISENHELDER J, HUNTER T, CAVENEE WK, ARDEN KC: Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc. Natl. Acad. Sci. USA (1999) 96(13):7421-7426.
53. KOPS GJ, DE RUITER ND, DE VRIES-SMITS AM, POWELL DR, BOS JL, BURGERING BM: Direcr control of the Forkhead transcription factor AFX by protein kinase B. Nature (1999) 398(6728):630-634.
54. TANG ED, NUNEZ G, BARR FG, GUAN KL: Negative regulation of the forkhead transcription factor FKHR by Akt. J. Biol. Chem. (1999) 274(24):16741-16746.
55. DIJKERS PF, MEDEMA RH, LAMMERS JW, KOENDERMAN L, COFFER PJ: Expression of the proapoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr. Biol. (2000) 10(19):1201-1204.
56. DE MARZO AM, MEEKER AK, EPSTEIN JI, COFFEY DS: Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am. J. Pathol. (1998) 153(3):911-919.
57. COTE RJ, SHI Y, GROSHEN S et al.: Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J. Natl. Cancer Inst. (1998) 90(12):916-920.
58. TSIHLIAS J, KAPUSTA LR, DEBOER G et al.: Loss of cyclin-dependenr kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. (1998) 58(3):542-548.
59. GUO Y, SKLAR GN, BORKOWSKI A, KYPRIANOU N: Loss of the cyclin-dependent kinase inhibitor p27 (Kip1) protein in human prostate cancer correlates with tumor grade. Clin. Cancer Res. (1997) 3(12):2269-2274. •• Links p27KIP1 loss to CaP progression.
60. DI CRISTOFANO A, DE ACETIS M, KOFF A, CORDON-CARDO C, PANDOLFI PP: PTEN and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet. (2001) 27(2):222-224. •• Data show that PTEN and p27 loss cooperate to drive prostatic tumourigenesis.
61. GOTTSCHALK AR, BASILA D, WONG M etal: p27Kip1 is required for PTEN-induced G1 growth arrest. Cancer Res. (2001) 61(5):2105-2111.
62. LI DM, SUN H: PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc. Natl. Acad. Sci. USA (1998) 95(26):15406-15411.
63. SUN H, LESCHE R, LI DM et al.: PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc. Natl. Acad. Sci. USA (1999) 96(11):6199-6204.
64. GRAFF JR, KONICEK BW, MCNULTY AM et al.: Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27KIP1 expression. J. Biol. Chem. (2000) 275:24500-24505. • Data show that the emergence of androgen-independence involves increased AKT activity and decreased p27KIP1 expression.
65. DIJKERS PF, MEDEMA RH, PALS C et al.: Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol. Cell. Biol. (2000) 20(24):9138-9148.
66. MAMILLAPALLI R, GAVRILOVA N, MIHAYLOVA VT et al.: PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27 (KIP1) through the ubiquitin E3 ligase SCF(SKP2). Curr. Biol. (2001) 11(4):263-267. • Demonstrates a link between AKT activation and p27KIP1 protein degradation.